Neurology Minute

In the December episode of the President's Spotlight, Dr. Jason Crowell speaks with Dr. Natalia Rost to provide an overview of the Academy's journey through 2025.  Show reference:  https://www.aan.com/about-the-aan/presidents-spotlight  

In the fourth installment of our series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses semantic variant PPA.  Show citations:  Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0  Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388  Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiat

In the third installment of our series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses nonfluent/agrammatic PPA.  Show citations:  Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0  Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388  Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsych

Dr. Alex Menze and Professor Hakan Cetin discuss the need to reevaluate the approach to diagnosing and treating seronegative myasthenia gravis.  Show citations:  Krenn M, Wagner M, Schuller H, et al. Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing. Neurology. 2025;105(8):e214177. doi:10.1212/WNL.0000000000214177 

Dr. Gregg Day and Professor Jonathan Rohrer discuss the significance of studying individuals at risk of developing genetic frontotemporal dementia, focusing on how early cognitive changes before symptoms appear can inform research and future therapeutic trials.  Show citation: Russell LL, Bouzigues A, Convery RS, et al. Executive Function Deficits in Genetic Frontotemporal Dementia: Results From the GENFI Study. Neurol Genet. 2025;11(4):e200248. Published 2025 Jul 21. doi:10.1212/NXG.0000000000200248 

In the second installment of our series on primary progressive aphasia (PPA), Dr. Rogan Magee discusses logopenic PPA.  Show citations:  Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0  Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388  Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR. eds. Neuropsychiatry and

In the first part of this series, Dr. Rogan Magee provides an introduction to primary progressive aphasia (PPA) and explains its three subtypes.  Show citations:  Grossman M, Seeley WW, Boxer AL, et al. Frontotemporal lobar degeneration. Nat Rev Dis Primers. 2023;9(1):40. Published 2023 Aug 10. doi:10.1038/s41572-023-00447-0  Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6 Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018;75(3):342-352. doi:10.1001/jamaneurol.2017.4309 Mandelli ML, Lorca-Puls DL, Lukic S, et al. Network anatomy in logopenic variant of primary progressive aphasia. Hum Brain Mapp. 2023;44(11):4390-4406. doi:10.1002/hbm.26388  Putcha D, Erkkinen M, Daffner KR. Functional Neurocircuitry of Cognition and Cognitive Syndromes. In: Silbersweig DA, Safar LT, Daffner KR.

In this episode of the Neurology Minute, Dr. Nara Miriam Michaelson delves into another women's history minute to discuss Sylvia Lawry. 

Dr. Jason Crowell and Dr. YuHong Fu discuss the importance of differentiating between dementia with Lewy bodies and Parkinson disease dementia.  Show citatiion:  Fu Y, Halliday GM. Dementia with Lewy bodies and Parkinson disease dementia - the same or different and is it important?. Nat Rev Neurol. 2025;21(7):394-403. doi:10.1038/s41582-025-01090-x 

Dr. Dan Ackerman and Dr. Isabel Hostettler discuss the diagnosis, risk factors, and prognosis of RCVS, highlighting the need to recognize symptoms and distinguish it from other causes of subarachnoid hemorrhage.  Show reference:  Hostettler IC, Ponciano A, Wilson D, et al. Outcomes After Reversible Cerebral Vasoconstriction Syndrome With Convexity Subarachnoid Hemorrhage: Individual Patient Data Analysis. Neurology. 2025;105(5):e213984. doi:10.1212/WNL.0000000000213984 

In the November episode of the President's Spotlight, Dr. Jason Crowell talks with Dr. Natalia Rost about the Centers for Medicare & Medicaid Services final rule for how physicians are reimbursed in 2026.  Show reference:  https://www.aan.com/about-the-aan/presidents-spotlight  

Dr. Aaron Zelikovich discusses a recent article on nipocalimab and its role in treating generalized myasthenia gravis.  Show citations:  Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116. doi:10.1016/S1474-4422(24)00498-8

Dr. Katherine Havard Coiro discusses the 2024 McDonald Criteria for Multiple Sclerosis and how to interpret cerebrospinal fluid.  Show reference:  Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Montalban, Xavier, et al. The Lancet Neurology, Volume 24, Issue 10, 850 - 865 

In this episode of the Neurology Minute, Dr. Alison Christy delves into another women's history minute to discuss Marcelle Lapicque. 

Dr. Alison Christy and Dr. Matthew Ryan Woodward discuss the complexities of status epilepticus, focusing on its definitions, the transition to refractory and super-refractory states, and the implications for treatment.  Show citation: Woodward MR, Brown JP, Kittner SJ, et al. Super-Refractory Status Epilepticus Diagnosis, Management, and Prognostication: An International Survey Study. Neurol Clin Pract. 2025;15(5):e200520. doi:10.1212/CPJ.0000000000200520  

In the second part of this two-part series, Dr. Bradley Ong explains the four clinical phases of a typical migraine attack.  Show citation:  Lipton RB, Stokes J, Evans CJ, et al. Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing. Headache. 2025;65(8):1355-1368. doi:10.1111/head.15024 

In part one of this two-part series, Dr. Bradley Ong discusses the prodrome phase of migraine and how it represents the earliest stage of the attack.  Show citation:  Lipton RB, Stokes J, Evans CJ, et al. Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing. Headache. 2025;65(8):1355-1368. doi:10.1111/head.15024 

In part two of this series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss gender disparities in the treatment of multiple sclerosis.  Show citation: Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907 

In part one of this two-part series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss what disease-modifying therapies can be safely continued and strategically timed when pregnancy is anticipated.  Show citation: Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907 

Dr. Alison Christy and Dr. Jennifer L. McGuire discuss neuroimaging findings linked to ICANS, exploring whether specific imaging patterns correlate with distinct neurologic symptoms.  Show citation:  McGuire JL, Pinto S, Erdogan EN, et al. Neuroimaging Findings in Children and Young Adults With Neurotoxicity After CAR T-Cell Therapy for B-Cell Malignancies. Neurology. 2025;105(7):e214086. doi:10.1212/WNL.0000000000214086